Trial Profile

Safety and efficacy of immune globulin subcutaneous (Human) 20% solution in patients with primary immunodeficiency disease

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Immune globulin (Primary)
Indications Immunodeficiency disorders
Focus Adverse reactions; Therapeutic Use

Most Recent Events

04 Jan 2022 New trial record
08 Nov 2021 Results presented at the 2021 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com